Atherosclerotic Cardiovascular Disease Primary and Secondary Prevention in Latino Subgroups

被引:0
|
作者
Kaufmann, Jorge [1 ]
Marino, Miguel [1 ,2 ]
Lucas, Jennifer A. [1 ]
Rodriguez, Carlos J. [3 ]
Boston, Dave [4 ]
Giebultowicz, Sophia [4 ]
Heintzman, John [1 ,4 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ Portland State Univ, Sch Publ Hlth, Biostat Grp, Portland, OR USA
[3] Albert Einstein Coll Med, Dept Med Epidemiol & Populat Hlth, Bronx, NY USA
[4] OCHIN, Portland, OR USA
关键词
atherosclerotic cardiovascular disease; Latino; nativity; disparities; UNITED-STATES; RISK-FACTORS; HEALTH; SERVICES; PREVALENCE;
D O I
10.1007/s11606-024-08822-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundStudies assessing equity in the prevention of atherosclerotic cardiovascular disease (ASCVD) for Latinos living in the USA collectively yield mixed results. Latino persons are diverse in many ways that may influence cardiovascular health. The intersection of Latino nativity and ASCVD prevention is understudied.ObjectiveTo determine whether disparities in ASCVD screening, detection, and prescribing differ for US Latinos by country of birth.DesignA retrospective cohort design utilizing 2014-2020 electronic health record data from a network of 320 community health centers across 12 states. Analyses occurred October 1, 2022, to September 30, 2023.ParticipantsNon-Hispanic White and Latino adults age 20-75 years, born in Cuba, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, and the USA.ExposuresEthnicity and country of birth.Main MeasuresOutcome measures included prevalence of statin eligibility, of having insufficient data to establish eligibility, odds of having a documented statin prescription, and rates of statin prescriptions and refills. We used covariate-adjusted logistic and generalized estimating equations logistic and negative binomial regressions to generate absolute and relative measures.Key ResultsAmong 108,672 adults, 23% (n = 25,422) were statin eligible for primary or secondary prevention of ASCVD using American College of Cardiology/American Heart Association guidelines. Latinos, born in and outside the USA were more likely eligible than Non-Hispanic White patients were (US-born Latino OR = 1.55 (95% CI = 1.37-1.75); non-US-born Latino OR = 1.63 (95% CI = 1.34-1.98)). The eligibility criteria that was met differed by ethnicity and nativity. Latinos overall were less likely missing data to establish eligibility and differences were again observed by specific non-US country of origin. Among those eligible, we observed no statistical difference in statin prescribing between US-born Latinos and non-Hispanic White persons; however, disparities varied by specific non-US country of origin.ConclusionEfforts to improve Latino health in the USA will require approaches for preventing and reversing cardiovascular risk factors, and statin initiation that are Latino subgroup specific.
引用
收藏
页码:2041 / 2050
页数:10
相关论文
共 50 条
  • [31] A Telemonitoring Program for Primary and Secondary Prevention of Cardiovascular Disease
    Nodari, Savina
    Lupi, Laura
    Glisenti, Fulvio
    Gensini, Gianfranco
    Papa, Ilaria
    Piazzani, Mariangela
    Fabbricatore, Davide
    Arabia, Gianmarco
    Gabbrielli, Francesco
    CIRCULATION, 2018, 138
  • [32] Statin use for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in breast cancer (BC) patients (pts).
    Melson, John W.
    Koethe, Benjamin
    Mohanty, Sharanya
    Babroudi, Seda
    Bao, Chen
    Chunduru, Amar
    Dwaah, Henry
    Finn, Matthew
    Jain, Annika
    Lalla, Mumtu
    Patnaik, Paras
    Studley, Rachael
    Buchsbaum, Rachel J.
    Huber, Kathryn
    Parsons, Susan K.
    Upshaw, Jenica N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] PRIMARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG SABENA FLYING PERSONNEL
    ANET, P
    BROUNS, H
    VANDENAB.KG
    DELESCLUSE, A
    MALCOLM, J
    AEROSPACE MEDICINE, 1972, 43 (10): : 1147 - +
  • [34] Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease An Overview of Systematic Reviews
    Karmali, Kunal N.
    Lloyd-Jones, Donald M.
    Berendsen, Mark A.
    Goff, David C., Jr.
    Sanghavi, Darshak M.
    Brown, Nina C.
    Korenovska, Liliya
    Huffman, Mark D.
    JAMA CARDIOLOGY, 2016, 1 (03) : 341 - 349
  • [35] Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews
    Karmali, K. N.
    Loyd-Jones, D. M.
    Berendsen, M. A.
    JAMA CARDIOLOGY, 2017, 2 (04) : 461 - 461
  • [36] Risk scoring in primary prevention of atherosclerotic cardiovascular disease: Strengths and limitations
    De Backer, Guy G.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (14) : 1531 - 1533
  • [37] Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease Advances in Diagnosis and Treatment
    Mora, Samia
    Manson, JoAnn E.
    JAMA INTERNAL MEDICINE, 2016, 176 (08) : 1195 - 1204
  • [38] Impact of Lipid Lowering Therapies on the Primary Prevention of Atherosclerotic Cardiovascular Disease
    Akruti P. Prabhakar
    Deepak Vedamurthy
    Dinesh K. Kalra
    Current Cardiovascular Risk Reports, 2025, 19 (1)
  • [39] Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease The Aspirin Dilemma
    Mora, Samia
    Shufelt, Chrisandra L.
    Manson, JoAnn E.
    JAMA INTERNAL MEDICINE, 2022, 182 (06) : 587 - 589
  • [40] Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults
    Mosher, Christopher L.
    Osazuwa-Peters, Oyomoare L.
    Nanna, Michael G.
    Macintyre, Neil R.
    Que, Loretta G.
    Palmer, Scott M.
    Jones, W. Schuyler
    O'Brien, Emily C.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (02):